Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL Master Protocol (niraparib vs platinum-taxane as neoadjuvant therapy in ovarian cancer)
2021-005392-39Phase 2Active
- Sponsor
- GSK
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of niraparib in ovarian cancer (2 arms), sponsored by GSK. Primary endpoint: Pre-interval debulking surgery overall response rate. Started Dec 2021; status: active.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2021-005392-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005392-39.